Showing 1 - 10 of 15
The valuation of multi-staged pharmaceutical R&D can be interpreted as a chain of real options. In valuing these compound option models, a crucial problem is how to deal with the different types of risk. Previous models, such as Cassimon et al. (2004), offer a closed-form solution for the...
Persistent link: https://www.econbiz.de/10010572681
Persistent link: https://www.econbiz.de/10005397423
Persistent link: https://www.econbiz.de/10005210122
Persistent link: https://www.econbiz.de/10011525390
Persistent link: https://www.econbiz.de/10012132471
Persistent link: https://www.econbiz.de/10011563285
Persistent link: https://www.econbiz.de/10011662027
Persistent link: https://www.econbiz.de/10011537964
Persistent link: https://www.econbiz.de/10014335108
Persistent link: https://www.econbiz.de/10012316624